Efficacy Of Two Kinds Of Anti - VEGF Drugs In Vitreous Cavity Injection In The Treatment Of Retinal Branch Vein Occlusion With Macular Edema

Purpose:To evaluate and compare the efficacy and safety of intravitreal injection of two Anti-Vascular Endothelial Grouth Factors to treat branch retinal vein occlusion with macular edema.Methods:Retrospectively alalysis the patients from April to Decem-ber in 2014,who were diagnosed with branch retinal vein occlusion with macular edema by fundus examination, optical coherence tomograghy (OCT) and fundus flourescein angiography(FFA).36 eyes of 36 patients were collected,15 patients got intravitreal injction of ranibizumab (Lucentis) 0.5mg/0.05ml once,21 patients got injection of Conbercept 0.5mg/0.05ml once. And 10 patients had a degree of ischaemia of 5 or more papilla diameters,and got additional scatter photocoagulation.BCVA, intraocular pressure(IOP) and adverse events were recorded at pre-treated, 7days,1 month,2 month,3 month after treanment.CMT was recorded at pre-treated,1 month,2 months and 3months after treatment.Results:All 36 patients did not suffer from vitrous hemorrhage, pigment epithelial detachment,endophthalmitis,severe cataract and retina detachment.The mean BCVA (LogMAR) were 0.674±0.582、0.592± 0.471、0.214±0.201、0.465±0.376、0.643±0.420 in patients who got intravitreal injection of ranibizumab,and 0.694±0.574、0.612±0.371、 0.302±0.256、0.472±0.329、0.654±0.398 in conbercept at pre-treated and 7 days,1 month,2 months,3 months after treated.The mean BCVAs at 1 month and 2 months after treated were improved compared with pre-treated statistically(p<0.05). Improvement in mean BCVA from baseline is better in patients got intravitreal injection of ranibizumab than conbercep at 1 month after treated (p<0.05).CMTs were 610.6±363.5 um,301.5±244.0um,434.5±181.2um,593.4±301.9um in patients who got intravitreal injection of ranibizumab, while 602.0±342.2um,298.1± 253.lum,412.0±169.2um,610.6±245.8um in conbercept. It is decreased in CMT at 1 month and 2 month after treated compared with baseline at both ranibizumab and conbercept(P<0.05).There was no significant diff-erence in decline of CMT at each time after treated compared ranibi-zumab and conbercept.IOP was not increased statistically in both ranibizumab and conbercept compared pre-treated and post-treated.Conclusion:Intravitreal injection of both ranibizumab and conber-cept can improve visual acuity and decrease CMT in patients of branch retinal vein occlusion with macular edema. No adverse events were observed.. Ranibizumab has better inprvement in mean BCVA at short-time than conbercept,but the efficacy do not lasts too long. Conbercept have the advantage of cost over ranibizumab.